The evolving role of the histotechnologist in digital, value based healthcare.

Digital pathology and value-based healthcare (VBHC) are converging to reshape diagnostic medicine, yet the histotechnologist, whose tissue preparation enables every glass slide and whole slide image (WSI), remains largely invisible in this transformation. This article reframes the histotechnologist from technical operator to strategic value creator whose work directly shapes diagnostic accuracy, turnaround time, cost-per-case, and the quality metrics that increasingly govern reimbursement. Although laboratory testing accounts for roughly 2.3-2.5% of healthcare spending while informing nearly 70% of clinical decisions, its value-makers are seldom represented in VBHC planning. Mapping histotechnology onto established frameworks (Porter's value agenda and Clinical Lab 2.0), we show how bench-level practice translates into institutional performance. Because an estimated 60-70% of laboratory errors arise in the pre-analytical phase that histotechnologists primarily control, specimen fidelity becomes a measurable driver of clinical and financial outcomes. We argue that standardized, high-quality slide preparation is a prerequisite for reliable WSI and artificial intelligence (AI)-assisted diagnosis, positioning histotechnologists as the essential human quality-control layer for computational pathology. Amid workforce shortages, burnout, and reimbursement pressures including the 2014 US Protecting Access to Medicare Act (PAMA), we outline actionable workforce-development strategies to align histotechnology with digital, value-based care and realize the promise of AI in laboratory medicine.